Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 14 systematic review(s)/meta-analysis(es). ^[1-14]
• Nail Psoriasis: Brodalumab achieved the highest mean Nail Psoriasis Severity Index (NAPSI) improvement at 24 weeks (76.9%), followed by Etanercept (74%) and Ixekizumab (70.5%). Adalimumab and Ixekizumab had the highest proportions of patients reaching NAPSI 0 at 44.6% and 41%, respectively.
• Psoriasis Treatment Efficacy (the Psoriasis Area and Severity Index (PASI) 90): Bimekizumab, Ixekizumab, and Risankizumab were the most effective treatments for achieving PASI 90, with Brodalumab being less likely to reach PASI 90 but effective for achieving PASI 75 and PASI 100.
• Psoriatic Arthritis: Brodalumab was effective in treating psoriatic arthritis but was less likely to achieve PASI 90 compared to Guselkumab and other interleukin(IL)-17 inhibitors.
• Complete Resolution of Nail Psoriasis: Brodalumab had the second-highest probability of achieving complete nail psoriasis resolution at weeks 24-26.
• Brodalumab was associated with a higher rate of serious adverse events (SAEs) compared to placebo, including a higher rate of infections during the induction period, but showed comparable SAE rates to Ustekinumab and other IL inhibitors over a 52-week period.
• Brodalumab demonstrated an acceptable safety profile, with no increased risk of malignancy, major cardiac events, suicidal ideation, or fatal events, and had lower discontinuation rates due to adverse events compared to some TNF inhibitors.
• The safety profile of Brodalumab was consistent across different ethnicities, with no significant variations observed.